Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
← catalyst calendarNCT07581314 · readout ≤ 285 d
Sponsored by Telomir Pharmaceuticals, Inc. (industry) · TELO — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
76estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Triple-Negative Breast Cancer (TNBC)
- Advanced Triple-Negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
Intervention
- Drug: Zn-Telomir
Primary outcomes
what the primary-completion date above is the date OFPhase I: Incidence of Serious Adverse Events (SAEs) and incidence and severity of Treatment-Emergent AEs (TEAEs)
measured From first dose up to approximately 6 months
Phase II: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
measured From first recommended dose up to 4 months.
Permalink · TELO's whole pipeline · Catalyst calendar · Every registered study · What changed